Who makes Urokinase-Derived Peptide A6?

Urokinase-Derived Peptide A6 is developed by Gynecologic Oncology Group.

What development phase is Urokinase-Derived Peptide A6 in?

Urokinase-Derived Peptide A6 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Urokinase-Derived Peptide A6

Gynecologic Oncology Group · Phase 2 active Biologic

At a glance

Generic name	Urokinase-Derived Peptide A6
Also known as	A6, uPA-derived Peptide A6
Sponsor	Gynecologic Oncology Group
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Urokinase-Derived Peptide A6 CI brief — competitive landscape report
Urokinase-Derived Peptide A6 updates RSS · CI watch RSS
Gynecologic Oncology Group portfolio CI